Print
Email
Print Edition Stories
MHT's Marc Songini: Technology to keep seniors healthy
MHT's Efrain Viscarolasaga: Tech companies may have to wait for stimulus funds
MHT's Marc Songini: RI plans launch of cord blood center
Drug maker Idenix Pharmaceuticals Inc. said it plans to net $21.2 million from a common stock offering underwritten by Boston-based investment bank Leerink Swann LLC.
The offering, announced late Wednesday, involves 7.25 million Idenix shares priced at $3.14 a share.
Based in Cambridge, Idenix (NASDAQ: IDIX) aims to develop drugs for the treatment of human viral diseases. In February, the company signed a deal with GlaxoSmithKline PLC potentially worth more than $400 million.
As of June 30, Idenix had roughly $50.5 million in cash and cash equivalents on its books, up from around $42 million at the end of 2008. The company booked a net loss of $16.3 million in the second quarter, a slight improvement over the $18.9 million loss in the year-earlier period.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
